topotecan has been researched along with caffeine in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ardelt, B; Darzynkiewicz, RJ; Darzynkiewicz, Z; Gong, J; Kapuscinski, J; Traganos, F | 1 |
Dai, W; Darzynkiewicz, Z; Halicka, HD; Huang, X; Kurose, A; Tanaka, T; Traganos, F | 1 |
Mullangi, R; Mustafa, S; Pasha, K; Srinivas, NR; Venkatesh, P | 1 |
Davies, DB; Evstigneev, MP; Evstigneev, VP; Mosunov, AA; Parkes, HG | 1 |
1 review(s) available for topotecan and caffeine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for topotecan and caffeine
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Camptothecin; Cell Cycle; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Topotecan; Tumor Cells, Cultured | 1993 |
Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cytoplasm; DNA-Binding Proteins; Flow Cytometry; Histones; HL-60 Cells; Humans; Immunohistochemistry; Interphase; Kinetics; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Topotecan; Tumor Suppressor Proteins | 2005 |
Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?
Topics: Acute Kidney Injury; Adenosine A1 Receptor Antagonists; Animals; Caffeine; Drug Interactions; In Vitro Techniques; Injections, Intravenous; Kidney; Male; Microsomes, Liver; Rats; Rats, Wistar; Topotecan; Uranyl Nitrate; Xanthines; Xenobiotics | 2006 |
Quantification of the interceptor action of caffeine on the in vitro biological effect of the anti-tumour agent topotecan.
Topics: Antineoplastic Agents; Binding, Competitive; Caffeine; DNA; Humans; Models, Chemical; Topotecan | 2011 |